Concord Biotech Ltd.
NSE: CONCORDBIO · Pharmaceuticals
Snapshot
Unlock Concord Biotech Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Biotech Limited is a biopharmaceutical company specialising in the research, development, and manufacturing of fermentation-based active pharmaceutical ingredients (APIs). Its product portfolio spans therapeutic areas including immunosuppressants, oncology, anti-bacterials, and anti-fungals, alongside contract research and manufacturing services.
Business Model
The company generates revenue through the sale of complex fermentation-based APIs to global pharmaceutical markets and by providing contract research and manufacturing services. It leverages its expertise in fermentation and semi-synthesis to serve both domestic and international clients.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of its fermentation-based product portfolio and the increasing demand for complex APIs in global therapeutic markets. The company continues to focus on its contract research and manufacturing capabilities to capture additional market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards, and any failure to maintain compliance could lead to product recalls or manufacturing site restrictions.
- Manufacturing Complexity. The reliance on complex fermentation processes introduces operational risks, including potential yield fluctuations and technical challenges in scaling production.
- Market Competition. The pharmaceutical API sector is highly competitive, with pricing pressures from global generic manufacturers impacting profit margins.
- Geopolitical and Trade Risks. As an exporter, the company faces risks related to international trade policies, currency fluctuations, and changing regulatory requirements in foreign markets.
Start your research today
Unlock AI insights, financials, peers and live data on Concord Biotech Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,170 Cr
TTM · consolidated
NET PROFIT
₹279 Cr
TTM · consolidated
EPS
₹26.71
TTM · consolidated
RETURN ON EQUITY
14.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.8%
TTM · consolidated
P/E
43.6×
Q2 FY27 · consolidated
EV/EBITDA
28.8x
Q2 FY27 · consolidated
EBITDA MARGIN
38.7%
TTM · consolidated
NET PROFIT MARGIN
22.5%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Concord Biotech Ltd.CONCORDBIO | ₹13,031 Cr | 43.6× | 28.78 | 4.0% | 38.7% | 14.3% | 18.8% | -19.4% |
Jubilant Pharmova Ltd.JUBLPHARMA | ₹14,714 Cr | 42.6× | 12.90 | 16.3% | 15.0% | 5.3% | 6.5% | -14.0% |
Marksans Pharma LimitedMARKSANS | ₹13,880 Cr | 27.4× | 16.27 | 57.4% | 25.7% | 31.9% | 39.6% | +71.5% |
Corona RemediesCORONA | ₹13,147 Cr | 64.1× | 38.24 | — | 22.2% | 28.3% | 33.9% | — |
Sudeep PharmaSUDEEPPHRM | ₹12,066 Cr | 65.7× | 44.30 | — | 38.8% | 22.4% | 27.7% | — |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | ₹11,517 Cr | 38.5× | 16.00 | 9.2% | 15.6% | 9.2% | 13.8% | +59.1% |
As of Q2 FY27
Financials
Concord Biotech Ltd.
NSE: CONCORDBIO · Pharmaceuticals
Snapshot
Unlock Concord Biotech Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Biotech Limited is a biopharmaceutical company specialising in the research, development, and manufacturing of fermentation-based active pharmaceutical ingredients (APIs). Its product portfolio spans therapeutic areas including immunosuppressants, oncology, anti-bacterials, and anti-fungals, alongside contract research and manufacturing services.
Business Model
The company generates revenue through the sale of complex fermentation-based APIs to global pharmaceutical markets and by providing contract research and manufacturing services. It leverages its expertise in fermentation and semi-synthesis to serve both domestic and international clients.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of its fermentation-based product portfolio and the increasing demand for complex APIs in global therapeutic markets. The company continues to focus on its contract research and manufacturing capabilities to capture additional market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards, and any failure to maintain compliance could lead to product recalls or manufacturing site restrictions.
- Manufacturing Complexity. The reliance on complex fermentation processes introduces operational risks, including potential yield fluctuations and technical challenges in scaling production.
- Market Competition. The pharmaceutical API sector is highly competitive, with pricing pressures from global generic manufacturers impacting profit margins.
- Geopolitical and Trade Risks. As an exporter, the company faces risks related to international trade policies, currency fluctuations, and changing regulatory requirements in foreign markets.
Start your research today
Unlock AI insights, financials, peers and live data on Concord Biotech Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,170 Cr
TTM · consolidated
NET PROFIT
₹279 Cr
TTM · consolidated
EPS
₹26.71
TTM · consolidated
RETURN ON EQUITY
14.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.8%
TTM · consolidated
P/E
43.6x
Q2 FY27 · consolidated
EV/EBITDA
28.8x
Q2 FY27 · consolidated
EBITDA MARGIN
38.7%
TTM · consolidated
NET PROFIT MARGIN
22.5%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27